<DOC>
	<DOCNO>NCT00361634</DOCNO>
	<brief_summary>The purpose study ass whether DCE-MRI detect change active disease rheumatoid arthritis ( RA ) patient 4 , 8 12 week etanercept .</brief_summary>
	<brief_title>Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) Measure Response Etanercept Rheumatoid Arthritis</brief_title>
	<detailed_description>The current literature show promise magnetic resonance imaging ( MRI ) assess response therapy RA heterogeneity methodology semi-quantitative nature image analysis limit applicability . To evaluate ability DCE-MRI serve biomarker treatment-induced change RA associate synovial inflammation , reproducibility measurement effect size require . Additional endpoint synovial volume , bone erosion progression bone marrow edema-like change may also prove useful short-term assessment therapeutic intervention , explore context pharmacodynamic biomarker . It therefore critical conduct carefully design longitudinal study , focus identify key parameter related instrumentation data analysis , fully evaluate potential utility MRI early clinical development set . Importantly , study also demonstrate feasibility use DCE-MRI multiple center acquire useful information drive program decision . Expanded Access : Amgen provide expanded access clinical trial . Contact Amgen Call Center ( 866-572-6436 ) information .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Fulfillment 1987 American College Rheumatology ( ACR ) criteria RA disease duration &gt; 6 month Presence active disease ( define tender swollen joint ) least one wrist Suboptimal response methotrexate ( MTX ) define presence follow criterion ( base 68/66 joint count ) : 8 swollen joint AND 8 tender joint ( involvement wrist , finger least one region outside hand ) screen Must receive MTX stable dose &gt; 15 mg/week least 12 week prior baseline low dose acceptable otherwise tolerate ( toxicity documentation require ) . Patients currently receive disease modify antirheumatic drug ( DMARD ) therapy ( MTX , hydroxychloroquine sulfasalazine ) include tumor necrosis factor ( TNF ) antagonists ( etanercept , infliximab , adalimumab ) , abatacept , rituximab , leflunomide , cyclosporine , gold ( oral intramuscular injection ) within 8 week 5.5 halflives , whichever longer , screen Coexisting condition require medication alter vascular flow ( e.g. , nitrate , calcium channel blocker , ergot contain drug ) [ Potential effect antihypertensive migraine medication discuss Sponsor ] Comorbid autoimmune disorder include systemic lupus erythematosus Unable undergo MRI examination ( e.g. , presence pacemaker , defibrillator , implanted device anterior interbody cage , aneurysm clip pedicle screw allergic contrast agent tattoo [ area examination contain metallic pigment ] ) likely require sedation procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
	<keyword>DCE-MRI</keyword>
	<keyword>RA</keyword>
</DOC>